We are thrilled to announce that the highly anticipated N-Nitroso impurities of Amide and Indole have now been successfully developed e.g. N-Nitroso Orlistat , N-Nitroso Ropinirole , N-Nitroso Caprolactam ,N-Nitroso Gabapentin EP Impurity A , N-Nitroso Rizatriptan , N-Nitroso Zolmitriptan, N-Nitroso Naratriptan , N-Nitroso Tadalafil , N-Nitroso Eletriptan etc. are ready Stock
search icon
We are thrilled to announce that the highly anticipated N-Nitroso impurities of Amide and Indole have now been successfully developed e.g. N-Nitroso Orlistat , N-Nitroso Ropinirole , N-Nitroso Caprolactam ,N-Nitroso Gabapentin EP Impurity A , N-Nitroso Rizatriptan , N-Nitroso Zolmitriptan, N-Nitroso Naratriptan , N-Nitroso Tadalafil , N-Nitroso Eletriptan etc. are ready Stock

Menu

Nitroso

Nitrosamines are a group of chemical compounds that contain the nitroso functional group (NO) attached to an amine group (-NH). They can form in various ways, including through industrial processes, combustion, and certain chemical reactions, particularly involving nitrites and secondary amines. Nitrosamines are of concern because Many nitrosamines (N-Nitrosamines) are potent genotoxins; some have been classified as possible human carcinogens, although the degree of risk can vary depending on factors such as the amount of exposure and individual susceptibility. Synchemia Research Chemical is dedicated to thoroughly investigating the formation of nitroso impurities in APIs, including those related to the manufacturing processes. This approach indicates a proactive stance toward quality control and regulatory compliance. By exploring all potential sources of nitroso impurities, including those arising from the production processes themselves, Synchemia Research Chemical demonstrates a commitment to ensuring the purity, safety, and efficacy of their pharmaceutical products. Nitrosoamines, including N-Des-methyl Nitroso impurities, are important in pharmaceutical research and development due to their potential impact on drug safety and efficacy. Understanding and controlling the presence of these impurities is crucial for ensuring the quality and safety of pharmaceutical products. Can N-Nitrosamines exist in two different stable forms? N-nitrosamines substituted with two different alkyl groups can exist in two different stable forms distinguishable by several analytical methods. The two rotamers may differ in their overall dipole moment and therefore may posses different chemical and physical properties. Why do I see two peaks when analyzing N-Nitrosamines by HPLC or GC? HPLC and GC)analysis of N-nitrosamines may show two rotamers of the N-nitrosamine as two separate peaks. Whether two peaks are observed depends on the structure of the N-nitrosamine (i.e., symmetric vs. asymmetric) as well as the separation power of the analytical method.
We are the Synchemia Research Chemical specializes in manufacturing and exporting various nitrosoamine compounds, particularly focusing on N-Des-methyl Nitroso impurities of various APIs and nitroso compounds of direct APIs that contain secondary amines. By specializing in the synthesis and export of these compounds, Synchemia Research likely plays a significant role in supporting the pharmaceutical industry's efforts to meet regulatory requirements and ensure the highest standards of quality and safety in drug manufacturing.
download image Download catalogue

Pharmaceutical Reference Standards

N- Nitroso Ramipril Impurity E
N- Nitroso Ramipril Impurity E
CAT No SRC-N0143683
CAS No NA
Mol.F. C21H27N3O6
Mol.Wt. 417.5 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Ramipril EP Impurity A
N-Nitroso Ramipril EP Impurity A
CAT No SRC-N0143684
CAS No NA
Mol.F. C22H29N3O6
Mol.Wt. 431.5 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Ramipril EP Impurity B
N-Nitroso Ramipril EP Impurity B
CAT No SRC-N0143685
CAS No NA
Mol.F. C24H33N3O6
Mol.Wt. 459.5 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Ramipril EP Impurity H
N-Nitroso Ramipril EP Impurity H
CAT No SRC-N0143686
CAS No NA
Mol.F. C23H31N3O6
Mol.Wt. 445.5g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Ramipril EP Impurity I
N-Nitroso Ramipril EP Impurity I
CAT No SRC-N0143687
CAS No NA
Mol.F. C23H31N3O6
Mol.Wt. 445.5 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Ramipril EP Impurity J
N-Nitroso Ramipril EP Impurity J
CAT No SRC-N0143688
CAS No NA
Mol.F. C23H31N3O6
Mol.Wt. 445.5 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Ramipril EP Impurity N
N-Nitroso Ramipril EP Impurity N
CAT No SRC-N0143689
CAS No NA
Mol.F. C23H31N3O6
Mol.Wt. 445.5 g/mole
INV STATUS CUSTOM SYNTHESIS
Ramipril Nitroso Impurity 1
Ramipril Nitroso Impurity 1
CAT No SRC-N0143690
CAS No NA
Mol.F. C15H18N2O3 : HCl
Mol.Wt. 274.3 : 36.5 g/mole
INV STATUS CUSTOM SYNTHESIS
Ertapenem N-Nitroso Pro-maba Impurity
Ertapenem N-Nitroso Pro-maba Impurity
CAT No SRC-N0143691
CAS No NA
Mol.F. C12H13N3O4
Mol.Wt. 263.25 g/mole
INV STATUS IN STOCK
Nitrosamines Impurity 92
Nitrosamines Impurity 92
CAT No SRC-N0143692
CAS No NA
Mol.F. C7H9N5O
Mol.Wt. 179.2 g/mole
INV STATUS UNDER SYNTHESIS
N-Nitroso Rivaroxaban Open-Ring Acid D4
N-Nitroso Rivaroxaban Open-Ring Acid D4
CAT No SRC-N0143693
CAS No NA
Mol.F. C19H15D4ClN4O7S
Mol.Wt. 486.9 g/mole
INV STATUS CUSTOM SYNTHESIS
Revefenacin Nitroso Impurity 1
Revefenacin Nitroso Impurity 1
CAT No SRC-N0143694
CAS No NA
Mol.F. C21H26N4O3
Mol.Wt. 382.5 g/mole
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Rasagiline D3 (Possibility 2)
N-Nitroso Rasagiline D3 (Possibility 2)
CAT No SRC-N0143695
CAS No NA
Mol.F. C12H9D3N2O
Mol.Wt. 203.3 g/mole
INV STATUS CUSTOM SYNTHESIS
Rimegepant Nitroso Impurity 1
Rimegepant Nitroso Impurity 1
CAT No SRC-N0143696
CAS No NA
Mol.F. C15H23N5O3
Mol.Wt. 321.4 g/mole
INV STATUS CUSTOM SYNTHESIS
Rimegepant Nitroso Impurity 2
Rimegepant Nitroso Impurity 2
CAT No SRC-N0143697
CAS No NA
Mol.F. C10H15N5O
Mol.Wt. 221.3 g/mole
INV STATUS CUSTOM SYNTHESIS
Rimegepant Nitroso Impurity 3
Rimegepant Nitroso Impurity 3
CAT No SRC-N0143698
CAS No NA
Mol.F. C10H15N5O
Mol.Wt. 221.3 g/mole
INV STATUS CUSTOM SYNTHESIS

Let’s advance your research together.

Partner with us for specialized chemical materials and synthesis services that enable pharmaceutical innovation.